

1 – 2 NOVEMBER 2016 | CAPITAL HILTON | WASHINGTON DC

DON'T MISS THIS
SENIOR SUMMIT!
BOOK NOW!



BIG DATA IN PRECISION MEDICINE

PRACTICAL APPLICATIONS. REAL RESULTS.
MEET THE INNOVATORS TURNING THEORY INTO REALITY.

JOIN THE MOST EXCLUSIVE PRECISION MEDICINE
SUMMIT IN THE HEART OF WASHINGTON DC

PRECISION MEDICINE INNOVATORS CONFIRMED INCLUDE:



Dr Gregory Simon,
Executive Director,
Cancer Moonshot Task Force



Dr William Dalton,
CEO, **M2Gen** & Director, The
DeBartolo Family Personalized
Medicine Institute,
Moffitt Cancer Center



Dr Brad Perkins,
Chief Medical Officer,
Human Longevity, Inc



Dr Eric Neumann,
VP Knowledge Informatics,
Foundation Medicine



Dr Sandy Farmer,
Executive Director, Enterprise Scientific
& Technology Operations,
Pfizer



Dr Sean Khozin,
Senior Medical Officer, Office
of Hematology and Oncology
Products, **US FDA**

INNOVATION PARTNER:



GOLD SPONSORS:


NORTHROP GRUMMAN



SILVER SPONSORS:



BRONZE SPONSORS:



REGISTER NOW AT WWW.BIGDATALEADERSFORUM.COM



BIG DATA IN PRECISION MEDICINE

Phacilitate have assembled an expert speaker panel that will pull in all the key voices from tech innovators, Big Pharma, biotech, CROs, government, healthcare providers, payers and leading academics.

HEAR FROM ALL THESE INDUSTRY LEADERS:

Dr William Dalton,
CEO, **M2Gen** & Director, The DeBartolo
Family Personalized Medicine Institute,
Moffitt Cancer Center

Dr Gregory Simon,
Executive Director,
Cancer Moonshot Task Force

Jonathan Hirsch,
Founder and President,
Syapse

Dr Anthony Kerlavage,
Chief, Cancer Informatics Branch,
NCI

Dr Brad Perkins, Chief Medical Officer,
Human Longevity, Inc

Sandy Farmer,
Executive Director, Enterprise Scientific
Technology Operations,
Pfizer

Dr Gary Palmer,
CMO, President GPS Cancer Division,
NantHealth

Dr Eric Neumann,
VP Knowledge Informatics,
Foundation Medicine

Dr David Fenstermacher,
VP R&D Bioinformatics,
MedImmune

Dr Sean Khozin,
Senior Medical Officer, Office of
Hematology and Oncology Products,
US FDA

Prof David Smith, Chairman of the
Technology Assessment Group, Center for
Individualized Medicine, **Mayo Clinic**

Dr John Piccone,
Partner, Global Leader for Life Sciences
Offerings,
IBM Watson

Dr Ari Caroline,
Chief Analytics Officer,
**Memorial Sloan Kettering Cancer
Center**

Dr Slava Akmaev,
Chief Analytics Officer,
Berg Health

Dr John Wilbanks,
Chief Commons Officer,
Sage Bionetworks

Dr Paul Bleicher,
CEO,
Optum Labs

Dr Shuvayu Sen, Executive Director,
Outcomes Research and Access, **Merck**

Dr Cathy Critchlow,
Vice President for Observational
Research,
Amgen

Dr Ray Liu, Senior Director, Head of
Statistical Innovation, **Takeda**

Dr Lynn Hudson,
Chief Science Officer,
C-Path

Dr Oscar Marroquin, VP Clinical
Analytics, **UPMC**

Robert L. Grossman, Professor of
Medicine, Director the Center for Data
Intensive Science, and Chief Research
Informatics Officer for the Division of the
Biological Sciences, **University of
Chicago**

Dr Edward Abrahams,
President,
Personalized Medicine Coalition

Dr Wayne Danter,
CEO,
Critical Outcome Technologies

Dr Michael Morrissey,
Group Leader, Oncology Bioinformatics,
Novartis

Dr Robert Miller, Senior Director,
Quality & Guidelines; Medical Director,
CancerLinQ, ASCO

Dr Bevan Emma Huang,
Associate Scientific Director,
Janssen R&D

Dr Zachary Pitluk,
Vice President, Life Sciences,
Paradigm4, Inc

Larry Pickett,
VP & CIO,
Purdue Pharma

Dr Cliona Molony,
Head of Computational Biomedicine,
Pfizer

Dr Christopher Kinsinger,
Program Manager, Office of Cancer
Clinical Proteomics Research,
NCI

Dr Steven Wickstrom,
VP Research,
UnitedHealth Group

Dr Anastasia Christianson,
Directorate Head, Data Science and IT,
Frederick National Lab for Cancer
Research and SVP,
Leidos Biomedical Research

Dr Glenn Gerhard,
Chair, Department of Medical Genetics
and Molecular Biochemistry,
Temple University

Dr Sally John,
VP Genomics & Computational Biology,
Biogen

Dr Francis Kendall,
Digital Strategy Leader,
Genentech

Dr Hui Cao,
Executive Director, CoE for RWE, Global
Medical Affairs,
Novartis

Dr David Kaufman,
Executive Director, Translational Immuno-
Oncology,
Merck

Joseph Dudas,
Division Chief, Enterprise Analytics,
Mayo Clinic

Lisa G Berdan, PA, MHS,
Senior Director,
Duke Clinical Research Institute

Dr Emanuel Petricoin, Chief Scientific
Officer, **Perthera**

Dr Philip R.O. Payne, PhD, FACMI, Co-
Founder,
Signet Accel

Dr Chuck Cooper,
WW VP, Medical Affairs,
Diagnostics, BD

Dr Michael Gaziano,
Principal Investigator,
Million Veteran Programme

Dr Michele Russell-Einhorn,
Senior Director, Office for Human Studies,
Dana-Farber Cancer Institute

Dr Neil Gomes,
VP, Technology Innovation and Consumer
Experience,
**Thomas Jefferson University &
Jefferson Health**

Dr Nicolas Robine, Assistant Director,
Computational Biology, **New York
Genome Center**

Dr Dana Vuzman, Director, **Brigham
Genomic Medicine**

Dr Josephine Briggs,
Director,
**National Center for Complementary
and Integrative Health (NCCIH)**

Dr Brad Hirsch,
Senior Medical Director,
Flatiron

Sharon Terry,
President and CEO,
Genetic Alliance

Sally Okun,
Vice President, Advocacy, Policy & Patient
Safety,
PatientsLikeMe

Dr Daniel Auclair,
SVP Research,
MMRF

Dr Diane Wuest,
Associate Director, Precision Medicine
Initiative,
GNS Healthcare

Dr Barbara Bierer,
Faculty Co-Director, Multi-Regional Clinical
Trials Center of Brigham and Women's
Hospital and Harvard (MRCT Center),
Brigham and Women's Hospital

David Cocker,
Partner,
MDCPartners

Shawn Dolley,
Industry Leader, Health & Sciences,
Coudera

Dr Alex Sherman,
Director, Strategic Development &
Systems, Neurological Clinical Research
Institute,
Massachusetts General Hospital

Johan Brag,
Head of Imaging Phenomics,
MEDIAN Technologies

Dr Stephan Brock,
Chief Technology Officer,
olecular Health

Dr Ida Grundberg,
Business Development Manager,
link Proteomics

Dr Adam Resnick,
Director of the Center for Data Driven
Discovery in Biomedicine (D3b),
Children's Hospital of Philadelphia

Dr. David Yavin, President,
North America Medial EarlySign

Dr. Ran Goshen,
CMO,
Medial EarlySign

Dr Sam Shekar,
Chief Medical Officer, Health Division,
**Northrop Grumman Information
Systems**

THERE'S STILL TIME TO BOOK YOUR PASS AT
WWW.BIGDATALEADERSFORUM.COM

AGENDA

DAY 1 // 1st November 2016

OPENING CHAIR REMARKS

- How the Precision Medicine Initiative is the ultimate big data project – and how we can overcome massive logistical barriers to achieve results.
- How the combination of transformative technologies in data analytics and decision-making processes has the potential to revolutionize the accessibility of information for precision medicine

Dr Edward Abrahams, President, **Personalized Medicine Coalition**

8.50 THE CANCER MOONSHOT AND AN INFLECTION POINT IN CANCER CARE

Dr Gregory Simon, Executive Director, **Cancer Moonshot Task Force**

9.10 MOVING FROM A REACTIVE TO A PROACTIVE APPROACH TO CANCER CARE

Dr William Dalton, CEO, **M2Gen** & Director, The DeBartolo Family Personalized Medicine Institute, **Moffitt Cancer Center**

9.30 THE VALUE CASE OF PRIVATE PHARMA CLINICAL TRIAL DATA IN THE REAL-WORLD DATA CONTEXT

David Cocker, Partner, **MDCPartners**

Available technologies & designs based on big data that can be used for modern clinical trials

- With the increasingly rapid growth of data in life sciences, we are witnessing a major transition in the way research is conducted, from hypothesis-driven studies to data-driven stimulations of whole systems.
- New technology frameworks to develop trials which can be designed and executed faster, better and more economically.

9.50

WHERE BIG DATA AND PRECISION MEDICINE INTERSECT

- With more widely available health IT platforms to store and analyse vast amounts of electronic data from thousands of patients, how can we translate this information into actionable data for clinical research?
- Integrating genotype and clinical phenotype data in the context of a drug development research strategy

THE INTERSECTION OF BIG DATA AND HIGH PERFORMANCE COMPUTING ENABLES PREDICTIVE SCIENCE AND PRECISION MEDICINE

Dr Anastasia Christianson, Directorate Head, Data Science and IT, **Frederick National Lab for Cancer Research** and SVP, **Leidos Biomedical Research**

TRANSFORMING CANCER TREATMENT: INTEGRATING DATA TO DELIVER ON THE PROMISE OF PRECISION MEDICINE

Jonathan Hirsch, Founder and President, **Syapse**

Panellists:

Dr Steven Wickstrom, VP Research, **UnitedHealth Group**

Dr Daniel Auclair, SVP Research, **MMRF**

Dr Sandy Farmer, Executive Director, Enterprise Scientific Technology Operations, **Pfizer**

Dr Brad Hirsch, Senior Medical Director, **Flatiron**

11.10 Refreshments

Intelligent approaches to analysis in Big Data

11.50 CHAIRPERSON INTRODUCTION

Dr Zachary Pitluk, Vice President, Life Sciences, **Paradigm4, Inc**

11.55 VALUE OF APPLYING BIG DATA & ANALYTICS & COGNITIVE COMPUTING TO TACKLE THE INDUSTRY'S MOST PRESSING CHALLENGES

- How the combination of transformative technologies in data analytics and decision-making processes has the potential to revolutionize the accessibility of information for precision medicine
- The combination of medical imaging, genomics and molecular markers presents a new opportunity to link observations made at the cellular or molecular levels to macroscopic phenotypes

Dr John Piccone, Partner, Global Leader for Life Sciences Offerings, **IBM Watson**

12.15 CATCHING A WAVE: COHORT ANALYSIS OF ICU ECG AND CLINICAL DATA IN MIMIC III

Paradigm4 will present on creating a research environment based on 2800 complete patient records (ECG, clinical and outcomes) the Medical Information Mart for Intensive Care III (MIMIC III) - Re - MIMIC. Results from the application of signal processing and learning algorithms to identify patient cohorts will be presented.

Dr Zachary Pitluk, Vice President, Life Sciences, **Paradigm4, Inc**

12.35 PATIENT STRATIFICATION IN CLINICAL TRIALS: A PRAGMATIC BIG DATA APPROACH

Dr Slava Akmaev, Chief Analytics Officer, **Berg Health**

12.55 CLOSING PANEL DISCUSSION

Dr Wayne Danter, CEO, **Critical Outcome Technologies**

Clinical informatics applications –Clinical phenotype data: Promise & potential in drug development

11.50 CHAIRPERSON INTRODUCTION

Dr Nicolas Robine, Assistant Director, Computational Biology, **New York Genome Center**

11.55 CASUAL MACHINE LEARNING TO CREATE ACTIONABLE INSIGHTS FROM HEALTHCARE DATA

- Methods to integrate clinical, molecular, and real world data at large scales to build tremendous cloud-based holistic models for simulation experiments and inquiries of disease, personalized patient care, and event prediction
- Managing and deriving value from quantitative patient data to understand patient sub-populations, identify biomarkers of disease onset, progression, or patient stratification, assess clinical risk, and uncover mechanistic understanding of disease

Dr Diane Wuest, Associate Director, Precision Medicine Initiative, **GNS Healthcare**

12.15 MILLION VETERAN PROGRAM: A HEALTHCARE BASED GENOMIC COHORT

Dr Michael Gaziano, Million Veteran Programme Principal Investigator & Physician, **Brigham and Women's Hospital**

12.30 DERIVING EXTRAORDINARY CLINICAL INSIGHTS FROM ORDINARY MEDICAL DATA

Dr. David Yavin, President, **North America Medial EarlySign**
Dr. Ran Goshen, CMO, **Medial EarlySign**

12.45 LEVERAGING POPULATION ANALYTICS TO PREVENT, INTERCEPT AND CURE

Dr Bevan Emma Huang, Associate Scientific Director, **Janssen R&D**

1.00 PANEL: CLINICAL PHENOTYPE AND REAL WORLD DATA IN THE CONTEXT OF A DRUG DEVELOPMENT PORTFOLIO

Dr Cliona Molony, Head of Computational Biomedicine, **Pfizer**
Dr Shuvayu Sen, Executive Director, Outcomes Research and Access, **Merck**

Dr Bevan Emma Huang, Associate Scientific Director, **Janssen R&D**

13.30 Lunch

DON'T MISS YOUR CHANCE TO INFLUENCE THE FUTURE OF PRECISION MEDICINE -
BOOK NOW AT WWW.BIGDATALEADERSFORUM.COM

AGENDA

Bioinformatics application - Role of Big Data on identifying therapeutic targets and design new drugs

- 14.30 CHAIRPERSON INTRODUCTION
Prof David Smith, *Chairman of the Technology Assessment Group, Center for Individualized Medicine, Mayo Clinic*
- 14.35 TRANSFORMING THERAPEUTIC DISCOVERY AND DEVELOPMENT USING AN INTEGRATED GENOMICS STRATEGY
Dr David Fenstermacher, *VP R&D Bioinformatics, MedImmune*
- 14.55 HOW DO WE GET FROM REAL WORLD DATASETS TO CELL BIOLOGY
Dr Sally John, *VP Genomics & Computational Biology, Biogen*
- 15.15 DELIVERING SIMPLE™
Dr Gunjan Bhargava, *CEO, Innoplexus AG*
- 15.30 CLOSING PANEL: ROLE OF BIG DATA ON IDENTIFYING THERAPEUTIC TARGETS AND DESIGN NEW DRUGS
- Using computational analytics experimental platforms to generate and translate information of disease mechanisms into actionable/validated drug targets.
 - How is this to impact the traditional pharma development model? What are the implications on different therapeutic groups?
- Dr David Kaufman**, *Executive Director, Translational Immunology, Merck*
Further panellists:
Dr Ray Liu, *Senior Director, Head of Statistical Innovation, Takeda*

Subgroups from Real World Evidence, applications in clinical development

- 14.30 CHAIRPERSON INTRODUCTION
Dr Oscar Marroquin, *VP Clinical Analytics, UPMC*
- 14.35 AN ELECTRONIC HEALTH RECORD-LINKED BIOBANK FOR PRECISION MEDICINE RESEARCH
Dr Glenn Gerhard, *Chair, Department of Medical Genetics and Molecular Biochemistry, Temple University*
- 14.55 FROM DATA TO DECISION - INNOVATIONS IN REALWORLD EVIDENCE ANALYTICS
Stephan Brock, Ph.D., *Chief Technology Officer, Molecular Health*
- 15.35 PANEL - DATA-DRIVEN DECISION MAKING TO SUPPORT THE CLINICAL CONTINUUM
- Using patient-powered research that accelerates biomedical discoveries and provides clinicians with the knowledge to select the right treatments for the right patients at the right time.
 - Integrating claims and real world clinical data into a product value proposition, as well as directing new research focuses.
- Dr Eric Neumann**, *VP Knowledge Informatics, Foundation Medicine*
Dr Josephine Briggs, *Director, National Center for Complementary and Integrative Health (NCCIH)*
Dr Hui Cao, *Executive Director, CoE for RWE, Global Medical Affairs, Novartis*
Shawn Dolley, *Industry Leader, Health & Sciences, Cloudera*

16.00 Refreshments

Big data in multi-omics analytics and biomarker discovery

Building a bridge between cutting edge science and the delivery of genomic medicine in clinical practice

- 16.30 CHAIRPERSON INTRODUCTION
Dr Dana Vuzman, *Director, Brigham Genomic Medicine*
- 16.35 SUPPORTING TARGET IDENTIFICATION, BIOMARKER DISCOVERY AND PATIENT STRATIFICATION EFFORTS IN ONCOLOGY RESEARCH
Dr Michael Morrissey, *Group Leader, Oncology Bioinformatics, Novartis*
- 16.55 IMPLEMENTATION OF PRECISION CANCER ANALYSIS: DEMOCRATIZING PRECISION MEDICINE THROUGH MULTI-OMIC ANALYTICS
Dr Emanuel Petricoin, *Chief Scientific Officer, Perthera*
- 17.15 PRECISION PROTEOMICS ENABLING PERSONALIZED MEDICINE - RAPID, HIGH-THROUGHPUT SOLUTIONS FOR TARGETED BIOMARKER PROFILING
Dr Ida Grundberg, *Business Development Manager, Olink Proteomics*
- 17.35 MULTI-OMIC INTEGRATION OF CANCER DATASETS: NCI'S CLINICAL PROTEOMIC TUMOR ANALYSIS CONSORTIUM
Dr Chris Kinsinger, *Program Manager, NCI*

Using clinical phenotype data sources to aid drug discovery, drug repurposing and advancing clinical trials

- 16.30 CHAIRPERSON INTRODUCTION
Dr Philip R.O. Payne, PhD, FACMI, *Co-Founder, Signet Accel*
- 16.35 CLOSING THE GENOTYPIC-PHENOTYPIC LOOP: NEW DEVELOPMENTS
Dr Gary Palmer, *President, GPS Cancer Division and Chief Medical Officer, NantHealth*
- 16.55 DATA-DRIVEN APPROACHES TO CLINICAL RESEARCH: ACCELERATING DISCOVERY AND DELIVERING EVIDENCE
Dr Philip R.O. Payne, PhD, FACMI, *Co-Founder, Signet Accel*
- 17.15 REVOLUTIONIZING HUMAN HEALTH
Dr Brad Perkins, *Chief Medical Officer, Human Longevity, Inc*
- 17.35 CLOSING PANEL - DEVELOPMENT OF CLINIC-MOLECULAR DATA ANALYTICS TO PROVIDE A DEEPER UNDERSTANDING OF THE MECHANISM CONTROLLING THE CLINICAL RESPONSE TO EXPERIMENTAL THERAPEUTICS
- Speakers of the session plus:**
Robert L. Grossman, *Professor of Medicine, Director the Center for Data Intensive Science, and Chief Research Informatics Officer for the Division of the Biological Sciences, University of Chicago*



DON'T MISS YOUR CHANCE TO INFLUENCE THE FUTURE OF PRECISION MEDICINE -
BOOK NOW AT WWW.BIGDATALEADERSFORUM.COM

AGENDA

DAY 2 // 2nd November 2016

Development of clinical data standard and interoperability to give us the ability to exchange data with meaning and actionable insights

9.00	CHAIRPERSON INTRODUCTION	11:25	PANEL: CONTINUING THE DISCUSSION ON HOW WE CAN DERIVE CLINICAL INSIGHT FROM A VARIETY OF DATA SOURCES
9.05	EMPOWERING THE CREATION OF SCALABLE KNOWLEDGE TOOLS AT AN ACADEMIC MEDICAL CENTER Dr Ari Caroline , Chief Analytics Officer, Memorial Sloan Kettering Cancer Center		Working with stakeholders to harmonize efforts in data exchange through standardized processes
9.25	UNLOCKING THE EXPERIENCE OF OPEN ACCESS RESEARCH PLATFORMS FOR IMPROVING HEALTH IMPACTS Dr Sam Shekar , Chief Medical Officer, Health Division, Northrop Grumman Information Systems		Panellists: Dr Barbara Bierer , Faculty Co-Director, Multi-Regional Clinical Trials center of Brigham and Women's Hospital and Harvard (MRCT Center), Brigham and Women's Hospital Dr. Dee Amanze , Director of Clinical Consulting, Saama Technologies
9.45	LEVERAGING THE EXPANDING UNIVERSE OF BIG DATA TO GENERATE SCIENTIFIC AND REGULATORY INSIGHTS Dr Sean Khozin , Senior Medical Officer, Office of Hematology and Oncology Products, US FDA	11.50	ASCO'S BIG DATA CANCER DATABASE - Describe how ASCO's CancerLinQ has created a technology platform to bring big data insights to the point of care - Show how big data is being used to drive quality improvement in cancer care - Demonstrate how CancerLinQ supports discovery and innovation in precision medicine for researchers and life sciences Dr Robert Miller , Senior Director, Quality & Guidelines; Medical Director, CancerLinQ, ASCO
10.05	INITIATING CLINICAL TRIALS TRANSFORMATION - ARE VIRTUAL TRIALS A REALITY? Dr Lisa Berdan , Director, Global Megatrials, Duke University	12.05	ROUNDTABLE DISCUSSIONS 12.05-12.30 ROUNDTABLE TOPIC 1: HOW CAN YOU BRING ACTIONABLE DATA TO CLINICAL CARE TO ENABLE PRECISION MEDICINE? Bringing genomic sequencing and data science into the practice of clinical medicine Table hosts: Joseph Dudas , Division Chair, Enterprise Analytics, Mayo Clinic Dr Neil Gomes , Vice President, Technology Innovation and Consumer Experience, Thomas Jefferson University & Jefferson Health Dr. Dee Amanze , Director of Clinical Consulting, Saama Technologies Dr Alex Sherman , Director, Strategic Development & Systems, Neurological Clinical Research Institute, Massachusetts General Hospital Dr Philip R.O. Payne, PhD, FACMI , Co-Founder, Signet Accel
10.25	PANEL: AGGREGATING CLINICAL DATA ACROSS MULTIPLE SOURCES TO DRIVE DRUG DEVELOPMENT AND IMPROVE HEALTHCARE DELIVERY Panellists: Dr Lynn Hudson , Chief Science Officer, C-Path Dr Paul Bleicher , CEO, Optum Labs Dr Cathy Critchlow , Vice President for Observational Research, Amgen Dr Alex Sherman , Director, Strategic Development & Systems, Neurological Clinical Research Institute, Massachusetts General Hospital		ROUNDTABLE 2: PUTTING BIG DATA TO WORK: MAKING BIG DATA USEFUL ACROSS LARGE ORGANIZATIONS IS TABLESTAKES FOR THERAPEUTICS R&D Table host: Seven Bridges
10.55am	Morning refreshments		

12.30 Lunch

Creating a data-driven model for life science and healthcare

	CHAIRPERSON INTRODUCTION Dr Adam Resnick , Director of the Center for Data Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia
13.35	BIG DATA IN CANCER RESEARCH AND PRECISION MEDICINE Dr Anthony Kerlavage , Chief Cancer Informatics Branch, NCI/CBIIT
13.55	HOW CAN LEVERAGING THE CLOUD TO RETHINK AND RESTRUCTURE THEIR BUSINESS MODELS TOWARDS THE GOAL OF BETTER PATIENT OUTCOMES Larry Pickett , VP & CIO, Purdue Pharma
14.15	THE PHENOMICS REVOLUTION: UTILIZING AN IMAGING BIOMARKER PHENOTYPING SYSTEM WITHIN A CLOUD COMPUTING PLATFORM Understand the ground-breaking capabilities for processing and analyzing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes. Johan Brag , Head of Imaging Phenomics, MEDIAN Technologies

Re-evaluating the clinical trial paradigm using big data

13.30	CHAIRPERSON INTRODUCTION: Dr Alex Sherman , Director, Strategic Development & Systems, Neurological Clinical Research Institute, Massachusetts General Hospital
13.40	A PHARMA PERSPECTIVE ON USING EHRS IN CLINICAL TRIALS Dr Francis Kendall , Digital Strategy Leader, Genentech
14.00	DOES BIG DATA STIMULATE CHANGE AND GUIDE CLINICAL DEVELOPMENT? - Delivering actionable data supporting clinical trial excellence. - Are we asking the right questions from our data? - Empowering observations by bringing more information to patient/clinical trial subsets - Innovating existing clinical trial processes and systems via new tech approaches Bioxcel executive

14.30 Afternoon Refreshment

DON'T MISS YOUR CHANCE TO INFLUENCE THE FUTURE OF PRECISION MEDICINE -
BOOK NOW AT WWW.BIGDATALEADERSFORUM.COM

AGENDA

Designing research platforms to service patient populations

15:00	DESIGNING RESEARCH PLATFORMS TO SERVICE PATIENT POPULATIONS CHAIR & INTRODUCTION PRESENTATION • Connections between the meaningful use of data and meaningful engagement of the individuals providing that data • Unity with people who have had their genomes sequenced to help make their data scientifically useful through sharing and collaborative interpretation. Sharon Terry , <i>President and CEO</i> , Genetic Alliance	15:30	CONSENT AND BIOBANKING, CONSIDERATIONS FOR PRECISION MEDICINE Dr Michele Russell-Einhorn , <i>Vice President for Oncology Services, Central Oncology Review Division</i> , Schulman Associates IRB
15:15	DATA-DRIVEN INNOVATION FOR BETTER CARE AND WELL-BEING Sally Okun , <i>Vice President, Advocacy, Policy & Patient Safety</i> , PatientsLikeMe	15:45	CLOSING PANEL – PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL AND HEALTHCARE DATA SHARING • The potential benefits of providing shared access to personal digital information are becoming evident throughout medical research – but how do you find an appropriate balance between the potential advantages to the research community and respecting individual's rights? Speakers of the session plus: Mr John Wilbanks , <i>Chief Commons Officer</i> , Sage Bionetworks

16:15 Close of Conference



**THIS IS YOUR INVITATION TO JOIN THE LEADERS OF THE
PRECISION MEDICINE MOVEMENT!**

NETWORK WITH
UP TO
200
INNOVATORS AT
THIS EXECUTIVE
SUMMIT

86%
ATTENDEES
DIRECTOR LEVEL
AND ABOVE

COLLABORATE
& MEET NEW
PARTNERS TO
DRIVE YOUR DRUG
DEVELOPMENT
STRATEGY
FORWARD!

**DON'T MISS YOUR CHANCE TO INFLUENCE THE FUTURE OF PRECISION MEDICINE -
BOOK NOW AT WWW.BIGDATALEADERSFORUM.COM**

WHY YOU CAN'T AFFORD TO MISS IT



Meet the executives pioneering the use of unstructured clinical phenotype data to derive actionable insight for drug development



Gain a competitive edge by understanding how to collaborate and share data intelligently



Learn how future innovations in R&D will be driven by integrating real world data



Understand how machine learning and cognitive computing can bring value to drug development and clinical care



Understand how research platforms can be developed to build meaningful engagement with patients



Do all this in the home of the precision medicine initiative with the leaders driving this movement forward

COLLABORATION IS KEY TO PRECISION MEDICINE.
START NETWORKING & BUILDING YOUR SCHEDULE AT THE EVENT
NOW USING OUR ONLINE NETWORKING TOOL.

ENSURE YOU HAVE THE CHANCE TO INFLUENCE AND ENGAGE WITH
SENIOR EXECUTIVES IN AN INFORMAL ATMOSPHERE AT THIS HIGH
LEVEL SUMMIT.

PRECISION MEDICINE IS THE FUTURE - ENSURE YOU ARE PART OF IT, BOOK YOUR
CONFERENCE PLACE NOW AT WWW.BIGDATALEADERSFORUM.COM

STANDARD RATE

Delegate Type	Rates
Pharma / Biotech / CRO	\$2,495
Academic/Govt/Not-for-Profit	\$1,495
Technology/Service Provider	\$2,995



FOR INFORMATION ON:

Small company rates • Group discounts • 1-day attendance rate
Contact Phacilitate now on team@phacilitate.co.uk or call +44 (0)20 7384 7993

BOOK NOW AT WWW.BIGDATALEADERSFORUM.COM TO JOIN THE CONVERSATION!